DDrare: Database of Drug Development for Rare Diseases

Bms-986020 (DrugBank: BMS-986020)

2 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
85	Idiopathic interstitial pneumonia	1

51. Scleroderma [ 466 clinical trials, 536 drugs, (DrugBank: 142 drugs), 110 drug target genes, 210 drug target pathways]

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 466 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02588625 (ClinicalTrials.gov)	February 2016	26/10/2015	A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)	A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Scleroderma	Drug: BMS-986020;Other: Placebo	Bristol-Myers Squibb	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States;Canada;Poland;United Kingdom;France

85. Idiopathic interstitial pneumonia [ 514 clinical trials, 377 drugs, (DrugBank: 108 drugs), 97 drug target genes, 204 drug target pathways]

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 514 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01766817 (ClinicalTrials.gov)	January 31, 2013	10/1/2013	Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis	Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: BMS-986020;Drug: Placebo matching with BMS-986020	Bristol-Myers Squibb	NULL	Completed	40 Years	90 Years	All	325	Phase 2	United States;Australia;Chile;Colombia;Mexico;Peru